IP Library Granted Patent US 10,470,811
Granted Patent B2
US 10,470,811 · App. 15/332,902 · Granted Nov 12, 2019

Selective lung tissue ablation

Inventors: Peter P. Soltesz (Henderson, NV); Nikolai Aljuri (Hillsborough, CA); Ajit Nair (Pleasanton, CA)
Assignee: Pulmonx Corporation
A61B18/00A61B18/0206A61B18/082A61B18/1206A61B18/14A61B18/1492A61B18/1815A61B18/20A61M16/0057A61M16/0434A61M16/0463A61N5/1001A61N7/022A61B2018/0022A61B2018/00214A61B2018/00541A61B2018/00642A61B2018/00714A61B2018/00797A61B2018/00994A61B2018/0212A61B2018/044A61B2018/144A61B2018/1435A61B2018/1472A61B2018/1807A61B2018/1861
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,470,811
App. No.
15/332,902
Granted
Nov 12, 2019
Kind
B2
Abstract

Medical methods and systems are provided for effecting lung volume reduction by selectively ablating segments of lung tissue.

Claims (15)

1. A method for selectively ablating a treatment region in a lung comprising:

advancing a treatment apparatus through an airway toward the treatment region in the lung;

exchanging energy through the treatment apparatus to heat or cool the treatment region to a level to collapse at least a portion the treatment region; and

protecting adjacent regions in the lung and surrounding tissue from thermal damage by controlling pressure or temperature at the treatment region and at one or more untreated regions adjacent the treatment region.

2. A method as in claim 1 , wherein the tissue is raised to a temperature in the range from 40° C. to 95° C.

3. A method as in claim 1 , wherein the delivered energy comprises radiofrequency, alternating current, microwave, ultrasound, coherent light, incoherent light, radioisotopes, or a combination thereof.

4. A method as in claim 1 , further comprising advancing at least one additional treatment apparatus toward the treatment site in the lung region and delivering energy to the treatment site through at least two treatment apparatuses.

5. A method as in claim 1 , further comprising ventilating the patient's other lung.

6. A method as in claim 5 , further comprising ventilating untreated region(s) of the lung adjacent to the treated region.

7. A method as in claim 1 , further comprising controlling pressure and temperature simultaneously in the treatment site and in the one or more untreated regions adjacent the treatment site so that thermal damage to the non-targeted sites is minimized.

8. A method as in claim 1 , further comprising introducing an electrically or thermally conducting fluid into the treatment site to improve energy distribution.

9. A method as in claim 8 , further comprising deploying isolation barriers to inhibit the conductive fluid from migrating from the treatment site.

10. A method as in claim 1 , wherein the treatment site comprises an entire lobe of the lung.

11. A method as in claim 1 , further comprising monitoring the temperature within the treatment site and controlling the energy exchange to maintain a temperature within a desired range.

12. A method as in claim 1 , further comprising: testing the patient to determine if the treatment site is subject to collateral ventilation; and ablating the treatment site only if the treatment site is subject to collateral ventilation.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Mar 4, 2026
From: CANADIAN IMPERIAL BANK OF COMMERCE
To: PULMONX CORPORATION
Reel/Frame 075028/0274 →
SECURITY INTEREST Recorded Mar 2, 2026
From: PULMONX CORPORATION
To: PERCEPTIVE CREDIT HOLDINGS V, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 075012/0453 →
SECURITY INTEREST Recorded Jan 27, 2026
From: PULMONX CORPORATION
To: CANADIAN IMPERIAL BANK OF COMMERCE
Reel/Frame 074570/0001 →
RELEASE OF SECURITY INTEREST Recorded Sep 30, 2020
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: PULMONX CORPORATION
Reel/Frame 053952/0044 →
RELEASE OF SECURITY INTEREST Recorded Sep 30, 2020
From: BOSTON SCIENTIFIC CORPORATION
To: PULMONX CORPORATION
Reel/Frame 053953/0548 →
SECURITY INTEREST Recorded Mar 2, 2020
From: PULMONX CORPORATION
To: CANADIAN IMPERIAL BANK OF COMMERCE
Reel/Frame 052916/0213 →
MERGER Recorded Apr 23, 2019
From: PULMONX
To: PULMONX CORPORATION
Reel/Frame 048964/0563 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2019
From: SOLTESZ, PETER P.; ALJURI, NIKOLAI; NAIR, AJIT
To: PULMONX
Reel/Frame 048643/0165 →
SECURITY INTEREST Recorded Jul 26, 2017
From: PULMONX CORPORATION
To: BOSTON SCIENTIFIC CORPORATION
Reel/Frame 043349/0725 →
SECURITY INTEREST Recorded May 15, 2017
From: PULMONX CORPORATION
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 042466/0349 →